Solid Biosciences Inc (NASDAQ:SLDB) Director Life Sciences Maste Perceptive purchased 2,822,581 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were purchased at an average price of $4.65 per share, with a total value of $13,125,001.65. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

NASDAQ SLDB traded down $0.37 during trading hours on Monday, hitting $5.45. The company had a trading volume of 777,976 shares, compared to its average volume of 714,938. Solid Biosciences Inc has a 52 week low of $4.32 and a 52 week high of $54.54. The company’s 50 day moving average is $5.11. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.99 and a quick ratio of 6.99. The company has a market capitalization of $206.09 million, a price-to-earnings ratio of -2.42 and a beta of 2.09.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Monday, May 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.22). Sell-side analysts forecast that Solid Biosciences Inc will post -3.09 earnings per share for the current year.

Several research firms have recently weighed in on SLDB. Citigroup set a $6.00 price target on Solid Biosciences and gave the stock a “hold” rating in a research note on Thursday, May 16th. ValuEngine downgraded Woodward, Inc.Common Stock from a “buy” rating to a “hold” rating in a research note on Tuesday, April 9th. Credit Suisse Group set a €19.00 ($22.09) price target on K&S and gave the stock a “neutral” rating in a research note on Tuesday, May 14th. Zacks Investment Research downgraded H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Finally, Goldman Sachs Group downgraded E.ON SE Sponsored ADR (Germany) from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 14th. Two investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $6.35.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in shares of Solid Biosciences by 56.0% during the 4th quarter. BlackRock Inc. now owns 1,214,410 shares of the company’s stock valued at $32,546,000 after acquiring an additional 436,161 shares during the last quarter. Emory University boosted its position in shares of Solid Biosciences by 335.0% during the 1st quarter. Emory University now owns 298,887 shares of the company’s stock valued at $2,750,000 after acquiring an additional 230,173 shares during the last quarter. Spark Investment Management LLC boosted its position in shares of Solid Biosciences by 78.7% during the 1st quarter. Spark Investment Management LLC now owns 318,100 shares of the company’s stock valued at $2,926,000 after acquiring an additional 140,141 shares during the last quarter. Matisse Capital bought a new stake in shares of Solid Biosciences during the 1st quarter valued at about $604,000. Finally, Marshall Wace LLP boosted its position in shares of Solid Biosciences by 226.2% during the 1st quarter. Marshall Wace LLP now owns 69,813 shares of the company’s stock valued at $642,000 after acquiring an additional 48,409 shares during the last quarter. Institutional investors and hedge funds own 59.41% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: What does a dividend yield signify to investors?

Insider Buying and Selling by Quarter for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.